Relumina Non-Inferior to Leuprorelin in Japan PIII Study for Endometriosis: ASKA

March 16, 2021
ASKA Pharmaceutical said on March 15 that its gonadotropin-releasing hormone (GnRH) antagonist Relumina Tablets (relugolix) demonstrated non-inferiority to leuprorelin in a PIII comparative study conducted in 335 endometriosis patients with pelvic pain in Japan. In the study, patients received relugolix...read more